| Metric | Value ($ M) | Q1 FY25 |
|---|---|---|
| Revenue | 21.10 | 1574.6% |
| Total Income | 21.10 | 1574.6% |
| Expenditure | 22.10 | 18.0% |
| PBT | — | |
| Net Profit | -1.04 | 95.9% |
| OPM | -4.72% | |
| NPM | -4.94% | |
| EPS | 0.00 | 100.0% |
Lexicon Reports Q1 2026 Revenue of $21.1 Million
07 May 2026 · 7 May, 5:07 pm
Summary
Lexicon Pharmaceuticals reported first quarter 2026 financial results, with total revenues of $21.1 million, including $20.0 million from a milestone payment from Novo Nordisk and $1.1 million from INPEFA sales. The net loss for the quarter was $1.0 million, or less than $0.01 per share. The company's cash, investments, and restricted cash totaled $199.7 million as of March 31, 2026. Lexicon is focused on advancing its clinical programs, including sotagliflozin and LX9851, and anticipates several pivotal milestones in the coming months.
Key Highlights
- 1
Lexicon Pharmaceuticals reported total revenues of $21.1 million for the first quarter of 2026.
- 2
Development milestone revenue from the license agreement with Novo Nordisk contributed $20.0 million to the total revenue.
- 3
Net sales of INPEFA amounted to $1.1 million in the first quarter of 2026.
- 4
The net loss for the first quarter of 2026 was $1.0 million, or less than $0.01 per share.
- 5
As of March 31, 2026, Lexicon had $199.7 million in cash, investments, and restricted cash.
- 6
Novo Nordisk initiated a Phase 1 study of LX9851, triggering a $10 million milestone payment to Lexicon in 2026.
- 7
Lexicon anticipates SONATA-HCM to be fully enrolled mid-2026, with topline results expected in the first quarter of 2027.
Management Comments
Mike Exton
Ph.D.
“We have been intently focused on progressing our late and early-stage development pipeline in cardiometabolism and we are now well positioned to achieve several pivotal milestones as a result of those efforts. Over the next 12 months, those events potentially include the announcement of topline data from our ongoing registrational trial of sotagliflozin in hypertrophic cardiomyopathy, U.S. regulatory approval of ZYNQUISTA as the first adjunct to insulin for glycemic management in people with type 1 diabetes and the completion of initial Phase 1 development of LX9851 by our licensee, Novo Nordisk. Taken together, we believe these events have the potential to be transformative for Lexicon’s future.”
Scott Coiante
“Following our capital raise, receipt of two development milestones from Novo Nordisk earlier this year and our recently announced loan facility, our operations are now underpinned by a strengthened balance sheet,” “We remain focused on disciplined capital allocation as we continue to advance our clinical programs and seek to maximize long-term shareholder value.”
Informational and educational content only. Not investment advice.